NCT06104319CompletedPhase 2
Dose Exploration Study of GSK4532990 in. Participants With NASH or Suspected NASH
A Phase 2a, Single Dose, Open-label, Dose Exploration Study to Assess the PK-PD Activity, Safety, and Tolerability of GSK4532990 in Adult. Participants With NASH or Suspected NASH
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to understand how the drug GSK4532990 is processed in the body (pharmacokinetics) and how it works in the liver (pharmacodynamics) as well as to ensure it is safe and well-tolerated. The total study duration for each participant will be approximately 24-36 weeks.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 61 (actual)
- First submitted
- 23 Oct 2023
- Start date
- 22 Jan 2024
- Primary completion date
- 23 Sept 2025
- Lead sponsor
- GlaxoSmithKline
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT06104319
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 61
- From 22 Jan 2024 to the primary completion date, 23 Sept 2025
- 11 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Known weight loss of ≥5% within 3 months prior to Screening.
- Weight reduction surgery or procedures within 2 years of Screening.
Other illness
- Cirrhosis or current unstable liver or biliary disease.
- Other causes of liver disease including, but not limited to, alcohol-related liver disease, autoimmune disorders.
Other
- Individuals who meet any of the following exclusion criteria will not be eligible to participate in the study:
- Any contraindication to undergoing liver biopsy.
- Any contraindication to undergoing Magnetic Resonance Imaging or FibroScan®.
Who the study is looking for
- Participant must be 18 to 75 years of age.
- Participant must be capable of giving signed informed consent which includes compliance with the requirements and restrictions listed for the study.
- Participants who have proven diagnosis of NASH or suspected NASH based on defined study criteria.
- Participants must meet predefined stable use requirements of concomitant medications based on study criteria.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| - Coordinator of this site? Confirm its status | Austin | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Brandon | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Chula Vista | United States | Unknown status |
| - Coordinator of this site? Confirm its status | El Dorado | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Indianapolis | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Marrero | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Miami | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Miami Lakes | United States | Unknown status |
| - Coordinator of this site? Confirm its status | Montclair | United States | Unknown status |
| - Coordinator of this site? Confirm its status | San Antonio | United States | Unknown status |
| - Coordinator of this site? Confirm its status | San Diego | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.